ATE539756T1 - Prostaglandinsubstanzen für die behandlung von fettsucht - Google Patents

Prostaglandinsubstanzen für die behandlung von fettsucht

Info

Publication number
ATE539756T1
ATE539756T1 AT03758747T AT03758747T ATE539756T1 AT E539756 T1 ATE539756 T1 AT E539756T1 AT 03758747 T AT03758747 T AT 03758747T AT 03758747 T AT03758747 T AT 03758747T AT E539756 T1 ATE539756 T1 AT E539756T1
Authority
AT
Austria
Prior art keywords
obesity
prostagland
substances
treatment
compound
Prior art date
Application number
AT03758747T
Other languages
German (de)
English (en)
Inventor
Ryuji Ueno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Ag filed Critical Sucampo Ag
Application granted granted Critical
Publication of ATE539756T1 publication Critical patent/ATE539756T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03758747T 2002-10-23 2003-10-22 Prostaglandinsubstanzen für die behandlung von fettsucht ATE539756T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42033602P 2002-10-23 2002-10-23
PCT/JP2003/013453 WO2004037268A1 (en) 2002-10-23 2003-10-22 Prostaglandin compounds for the treatment of obesity

Publications (1)

Publication Number Publication Date
ATE539756T1 true ATE539756T1 (de) 2012-01-15

Family

ID=32176556

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03758747T ATE539756T1 (de) 2002-10-23 2003-10-22 Prostaglandinsubstanzen für die behandlung von fettsucht

Country Status (11)

Country Link
US (1) US8114911B2 (cg-RX-API-DMAC7.html)
EP (1) EP1562604B1 (cg-RX-API-DMAC7.html)
JP (1) JP4705782B2 (cg-RX-API-DMAC7.html)
AT (1) ATE539756T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003274735B2 (cg-RX-API-DMAC7.html)
CA (1) CA2502439C (cg-RX-API-DMAC7.html)
DK (1) DK1562604T3 (cg-RX-API-DMAC7.html)
ES (1) ES2379652T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ539582A (cg-RX-API-DMAC7.html)
PT (1) PT1562604E (cg-RX-API-DMAC7.html)
WO (1) WO2004037268A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1641462B1 (en) 2003-07-03 2010-11-24 Sucampo AG Enteric coated composition comprising prostaglandin analogs as chloride channel opener
CA2681668C (en) 2006-03-23 2014-04-01 Michael S. Singer Compositions comprising prostaglandin f2-alpha analogs and methods for reducing body fat
CA2866067C (en) 2011-01-19 2015-04-21 Topokine Therapeutics, Inc. Uses of certain f-series prostaglandin analogs for treating diabetes and dyslipidemia
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
AU2013347949A1 (en) 2012-11-21 2015-06-11 Velakine Therapeutics, Inc. Methods and compositions for locally increasing body fat
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
ES2785382T3 (es) 2013-04-12 2020-10-06 Allergan Inc Liberación sostenida de bimatoprost, análogos de bimatoprost, prostamidas y prostaglandinas para la reducción de grasa
NO2753788T3 (cg-RX-API-DMAC7.html) 2013-05-10 2018-06-16
US9820993B2 (en) 2013-05-15 2017-11-21 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
US10188661B2 (en) 2014-06-27 2019-01-29 Topokine Therapeutics, Inc. Topical dosage regimen
US11452703B2 (en) 2020-05-21 2022-09-27 Peregrine Ophthalmic PTE LTD. Methods and compositions for reducing adipocyte numbers

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US388919A (en) * 1888-09-04 Benjamin scables
US3888919A (en) * 1971-03-11 1975-06-10 Upjohn Co 11,15 dimethyl pge' 1 'and pgf' 1'
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
JP2597629B2 (ja) * 1988-02-26 1997-04-09 株式会社 上野製薬応用研究所 １３，１４−ジヒドロ−１５−ケトプロスタグランジン類の安定化
NZ226199A (en) * 1988-09-15 1991-05-28 Ueno Seiyaku Oyo Kenkyujo Kk 13,14-dihydro-15-keto-pgf derivatives and pharmaceutical compositions
NZ226198A (en) * 1988-09-15 1991-05-28 Ueno Seiyaku Oyo Kenkyujo Kk Fervescence (temperature raising) composition comprising 15-keto-pge
JPH085794B2 (ja) * 1989-07-27 1996-01-24 株式会社上野製薬応用研究所 高脂質血症処置・血中脂質成分低下剤
DE69006964T2 (de) * 1989-07-27 1994-06-09 Ueno Seiyaku Oyo Kenkyujo Kk Behandlung von Hyperlipidemia mit 15-keto-Prostaglandin-Verbindungen.
US5234954A (en) * 1989-07-27 1993-08-10 K.K. Ueno Seiyaku Oyo Kenkyujo Treatment of hyperlipidemia with 15-keto-prostaglandin compounds
TW249226B (cg-RX-API-DMAC7.html) 1990-04-04 1995-06-11 Aderk Ueno Kk
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
US6022897A (en) * 1995-04-25 2000-02-08 The Salk Institute For Biological Studies Selective modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof
WO1997047595A1 (en) 1996-06-10 1997-12-18 R-Tech Ueno, Ltd. Endothelin antagonist
DE69900847T2 (de) * 1998-04-17 2002-09-12 Tufts College Map kinase-inhibitoren zur behandlung von durch tnf-alpha induzierte lipolyse- verursachte krankheiten
JP2000157260A (ja) * 1998-11-26 2000-06-13 Toyobo Co Ltd 初代前駆脂肪細胞の分化誘導方法及びその分化用培地
JP4332316B2 (ja) 1999-10-15 2009-09-16 スキャンポ・アーゲー 二環式化合物組成物およびその安定化方法
US6414016B1 (en) 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
PT1389116E (pt) 2001-05-18 2008-04-11 Sucampo Ag Composição de indução catártica
BR0212233A (pt) 2001-08-31 2004-10-05 Sucampo Ag Abridor de canal de cloreto
AR037524A1 (es) 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
US7732487B2 (en) 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel
KR101164838B1 (ko) 2002-12-27 2012-07-11 수캄포 아게 복부 불쾌감 치료용 프로스타글랜딘의 유도체
EP1641462B1 (en) 2003-07-03 2010-11-24 Sucampo AG Enteric coated composition comprising prostaglandin analogs as chloride channel opener
TWI387454B (zh) 2004-09-02 2013-03-01 蘇坎波公司 治療胃腸道疾病之方法及組成物
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
ES2371658T3 (es) 2005-04-12 2012-01-05 Sucampo Ag Uso combinado de compuesto de prostaglandina e inhibidor de la bomba de protones para el tratamiento de trastornos gastrointestinales.

Also Published As

Publication number Publication date
EP1562604B1 (en) 2012-01-04
ES2379652T3 (es) 2012-04-30
EP1562604A1 (en) 2005-08-17
JP4705782B2 (ja) 2011-06-22
NZ539582A (en) 2007-07-27
PT1562604E (pt) 2012-04-09
WO2004037268A1 (en) 2004-05-06
US20050261373A1 (en) 2005-11-24
DK1562604T3 (da) 2012-04-02
US8114911B2 (en) 2012-02-14
JP2006506381A (ja) 2006-02-23
AU2003274735A1 (en) 2004-05-13
CA2502439A1 (en) 2004-05-06
CA2502439C (en) 2011-11-22
AU2003274735B2 (en) 2008-12-04

Similar Documents

Publication Publication Date Title
ATE368031T1 (de) Neue gamma secretase inhibitoren
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
ATE433447T1 (de) Pyrimiidinverbindungen
NO20070606L (no) Inhibitorer av IAP
ATE318267T1 (de) Einige alkylendiamin-substituierte heterocyclen
CY1113578T1 (el) 2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια
EA200701467A1 (ru) Пирролидиновые ингибиторы иап (ингибиторов апоптоза)
CY1105994T1 (el) Aναδιαταγμενες πεντανολες, μεθοδος για την παραγωγη αυτων και η χρηση αυτων ως αντιφλεγμονωδων
TW200517377A (en) New 2-pyridinylethylbenzamide compounds
ATE539756T1 (de) Prostaglandinsubstanzen für die behandlung von fettsucht
EA200601295A1 (ru) Производные 1,3-диоксана и их аналоги, применимые для лечения i.a. ожирения и диабета
DE60220385D1 (de) Benzimidazole zur behandlung sexueller fehlfunktionen
HRP20080057T3 (en) 9,10-alpha,alpha-oh-taxane analogs and methods for production thereof
ATE411287T1 (de) Neue metallproteinaseinhibitoren
ATE502631T1 (de) Verbindungen zur behandlung von stoffwechselstörungen
ATE359283T1 (de) Substituierte pyrazinonverbindungen zur behandlung von entzündungen
DE60327432D1 (de) Nützliche verbindungen für die behandlung von anthrax und hemmung des letalen faktors
DE60329326D1 (de) Tace inhibitoren
MA27549A1 (fr) N-sulfonyl-4-methylene-amino-3-hydroxy-2-pyridones
ATE346040T1 (de) Aryl-sulfonamide als serotonin-antagonisten für de behandlung von fettleibigkeit
NO20032406L (no) Anvendelse av 1-fenyl-3-dimetylaminopropanforbindelser for behandling av urininkontinens
DE602005011267D1 (de) Benzofuran- und benzothiophenderivate, die sich für die behandlung von herzkreislauferkrankungen eignen
EA200601106A1 (ru) Трициклические имидазопиридины для применения в качестве ингибиторов желудочной секреции
BR0214445B1 (pt) processos para a produção de compostos.
DK1353660T3 (da) Anvendelse af substituerede 6-dimethylaminomethyl-1-phenylcyclohexanforbindelser til behandling af urininkontinens